Shares of Sellas Life Sciences surged 8.2% to $14.61 as investors digested a dramatic vote of confidence from Wall Street: Alliance Global analyst James Molloy raised his price target on the stock to $25 from $10 , a 150% increase that implies roughly 71% upside from today's price. For a company with no approved products and no revenue, the move underscores just how much is riding on a single late-stage clinical trial.
The Analyst Bet Hinges on Patients Living Longer Than Expected. Molloy maintained his Buy rating as the firm awaits the final two deaths in the ongoing Phase 3 REGAL trial, which is testing a cancer immunotherapy in blood-cancer patients who achieved a second remission.
The analyst views the ongoing delay in reaching those final events as a potentially significant positive, because it suggests patients are living longer than anticipated. In other words, the trial's slow pace is itself being read as evidence the drug may work — a bold interpretation that could just as easily unravel if final data disappoint.
A $1.5 Billion Company Running on Cash and Hope. Sellas' market value has surged from $73 million at the start of 2024 to over $1.5 billion by mid-2026 , a staggering run for a firm that still generates zero revenue. The company reported $107.1 million in cash as of March 31, 2026, with an additional $7.5 million received through warrant exercises in Q2. That cash cushion buys time, but Sellas' entire valuation depends on whether its drug can extend median survival in acute myeloid leukemia patients — from roughly 8 months to 12.6 months — a modest-sounding bar that carries enormous commercial implications.
Prediction Markets Are Optimistic, but Biotech Odds Often Mislead. Clinical-trial prediction markets have priced the probability of success for the therapy at roughly 83%. That's encouraging, but Phase 3 cancer trials historically fail about half the time. Recent amendments to executive change-of-control protections have also amplified speculation about potential acquisition interest , giving the stock an added speculative tailwind — essentially, a bet that a larger drug company might buy Sellas outright.
Volatility Tells the Real Story. The stock swung from $13.27 to $14.98 in just three trading days last week, with an 11% single-day drop on July 1 followed by a sharp rebound. This is a binary-outcome stock: the REGAL readout will either validate a billion-dollar thesis or collapse it. The new $25 target is a signal, not a guarantee.